US6407132B1
(en)
*
|
1997-07-25 |
2002-06-18 |
James Black Foundation Limited |
Substituted imidazole derivatives and their use as histamine H3 receptor ligands
|
GB9718913D0
(en)
*
|
1997-09-05 |
1997-11-12 |
Glaxo Group Ltd |
Substituted oxindole derivatives
|
DE19816624A1
(de)
*
|
1998-04-15 |
1999-10-21 |
Boehringer Ingelheim Pharma |
Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
|
DE19824922A1
(de)
*
|
1998-06-04 |
1999-12-09 |
Boehringer Ingelheim Pharma |
Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
|
US6319918B1
(en)
|
1998-06-04 |
2001-11-20 |
Boehringer Ingelheim Pharma Kg |
Substituted indolinones with kinase inhibitory activity
|
US6153634A
(en)
|
1998-12-17 |
2000-11-28 |
Hoffmann-La Roche Inc. |
4,5-azolo-oxindoles
|
KR20010108024A
(ko)
|
1998-12-17 |
2001-12-07 |
프리돌린 클라우스너, 롤란드 비. 보레르 |
단백질 키나제 억제제로서의 4,5-피라진옥신돌
|
BR9916216A
(pt)
*
|
1998-12-17 |
2001-09-11 |
Hoffmann La Roche |
4.5-azolo-oxindóis
|
JP2002532492A
(ja)
*
|
1998-12-17 |
2002-10-02 |
エフ.ホフマン−ラ ロシュ アーゲー |
サイクリン−依存性キナーゼ、特にcdk2のインヒビターとしての4−アルケニル(及びアルキニル)オキシドール
|
CA2354591A1
(en)
|
1998-12-17 |
2000-06-22 |
F. Hoffmann-La Roche Ag |
4-aryloxindoles as inhibitors of jnk protein kinases
|
EP1147214B1
(en)
|
1999-01-13 |
2011-01-05 |
The Research Foundation Of State University Of New York |
A novel method for designing protein kinase inhibitors
|
GB9904932D0
(en)
*
|
1999-03-04 |
1999-04-28 |
Glaxo Group Ltd |
Composition and method for preventing/reducing the severity of side effects of chemotherapy and/or radiation therapy
|
US6492398B1
(en)
*
|
1999-03-04 |
2002-12-10 |
Smithkline Beechman Corporation |
Thiazoloindolinone compounds
|
GB9904933D0
(en)
|
1999-03-04 |
1999-04-28 |
Glaxo Group Ltd |
Compounds
|
GB9904930D0
(en)
*
|
1999-03-04 |
1999-04-28 |
Glaxo Group Ltd |
Thiazoloindolinone compounds
|
US6624171B1
(en)
|
1999-03-04 |
2003-09-23 |
Smithkline Beecham Corporation |
Substituted aza-oxindole derivatives
|
US6358947B1
(en)
|
1999-05-04 |
2002-03-19 |
American Home Products Corporation |
Tetracyclic progesterone receptor modulator compounds and methods
|
US6399593B1
(en)
|
1999-05-04 |
2002-06-04 |
Wyeth |
Cyclic regimens using cyclic urea and cyclic amide derivatives
|
US6391907B1
(en)
|
1999-05-04 |
2002-05-21 |
American Home Products Corporation |
Indoline derivatives
|
US6358948B1
(en)
|
1999-05-04 |
2002-03-19 |
American Home Products Corporation |
Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
|
US6306851B1
(en)
|
1999-05-04 |
2001-10-23 |
American Home Products Corporation |
Cyclocarbamate and cyclic amide derivatives
|
US6339098B1
(en)
|
1999-05-04 |
2002-01-15 |
American Home Products Corporation |
2,1-benzisothiazoline 2,2-dioxides
|
US6417214B1
(en)
|
1999-05-04 |
2002-07-09 |
Wyeth |
3,3-substituted indoline derivatives
|
US6319912B1
(en)
|
1999-05-04 |
2001-11-20 |
American Home Products Corporation |
Cyclic regimens using 2,1-benzisothiazoline 2,2-dioxides
|
US6369056B1
(en)
|
1999-05-04 |
2002-04-09 |
American Home Products Corporation |
Cyclic urea and cyclic amide derivatives
|
US6355648B1
(en)
|
1999-05-04 |
2002-03-12 |
American Home Products Corporation |
Thio-oxindole derivatives
|
US6380235B1
(en)
|
1999-05-04 |
2002-04-30 |
American Home Products Corporation |
Benzimidazolones and analogues
|
US6444668B1
(en)
|
1999-05-04 |
2002-09-03 |
Wyeth |
Combination regimens using progesterone receptor modulators
|
US6423699B1
(en)
|
1999-05-04 |
2002-07-23 |
American Home Products Corporation |
Combination therapies using benzimidazolones
|
US6380178B1
(en)
|
1999-05-04 |
2002-04-30 |
American Home Products Corporation |
Cyclic regimens using cyclocarbamate and cyclic amide derivatives
|
US6498154B1
(en)
|
1999-05-04 |
2002-12-24 |
Wyeth |
Cyclic regimens using quinazolinone and benzoxazine derivatives
|
US6509334B1
(en)
|
1999-05-04 |
2003-01-21 |
American Home Products Corporation |
Cyclocarbamate derivatives as progesterone receptor modulators
|
US6462032B1
(en)
|
1999-05-04 |
2002-10-08 |
Wyeth |
Cyclic regimens utilizing indoline derivatives
|
US6407101B1
(en)
|
1999-05-04 |
2002-06-18 |
American Home Products Corporation |
Cyanopyrroles
|
US6329416B1
(en)
|
1999-05-04 |
2001-12-11 |
American Home Products Corporation |
Combination regimens using 3,3-substituted indoline derivatives
|
GB9911053D0
(en)
*
|
1999-05-12 |
1999-07-14 |
Pharmacia & Upjohn Spa |
4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents
|
DE19924401A1
(de)
*
|
1999-05-27 |
2000-11-30 |
Boehringer Ingelheim Pharma |
Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
|
AU6998000A
(en)
|
1999-08-27 |
2001-03-26 |
Boehringer Ingelheim Pharma Kg |
Substituted indolinones as tyrosine kinase inhibitors
|
ATE350044T1
(de)
*
|
1999-09-24 |
2007-01-15 |
Smithkline Beecham Corp |
Thrombopoietinmimetika
|
DE19949209A1
(de)
*
|
1999-10-13 |
2001-04-19 |
Boehringer Ingelheim Pharma |
In 5-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
|
UA75054C2
(uk)
*
|
1999-10-13 |
2006-03-15 |
Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг |
Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
|
US6762180B1
(en)
|
1999-10-13 |
2004-07-13 |
Boehringer Ingelheim Pharma Kg |
Substituted indolines which inhibit receptor tyrosine kinases
|
US6313310B1
(en)
|
1999-12-15 |
2001-11-06 |
Hoffmann-La Roche Inc. |
4-and 5-alkynyloxindoles and 4-and 5-alkenyloxindoles
|
YU54202A
(sh)
|
2000-01-18 |
2006-01-16 |
Agouron Pharmaceuticals Inc. |
Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
|
HN2001000008A
(es)
|
2000-01-21 |
2003-12-11 |
Inc Agouron Pharmaceuticals |
Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
|
WO2001056557A2
(en)
*
|
2000-02-05 |
2001-08-09 |
Vertex Pharmaceuticals Incorporated |
Compositions useful as inhibitors of erk
|
US6620818B1
(en)
*
|
2000-03-01 |
2003-09-16 |
Smithkline Beecham Corporation |
Method for reducing the severity of side effects of chemotherapy and/or radiation therapy
|
WO2001079198A1
(en)
|
2000-04-18 |
2001-10-25 |
Agouron Pharmaceuticals, Inc. |
Pyrazoles for inhibiting protein kinase
|
UA73119C2
(en)
|
2000-04-19 |
2005-06-15 |
American Home Products Corpoir |
Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
|
US6534531B2
(en)
*
|
2000-04-27 |
2003-03-18 |
Bristol-Myers Squibb Company |
Methods for preventing and treating alopecia induced by chemotherapy or radiotherapy
|
JP4216503B2
(ja)
*
|
2000-04-28 |
2009-01-28 |
アステラス製薬株式会社 |
βアミロイド産生抑制用医薬組成物
|
CY2010012I2
(el)
|
2000-05-25 |
2020-05-29 |
Novartis Ag |
Μιμητικα θρομβοποιητινης
|
GB0016454D0
(en)
|
2000-07-04 |
2000-08-23 |
Hoffmann La Roche |
Thienopyrrolidinones
|
WO2002012250A2
(en)
|
2000-08-09 |
2002-02-14 |
Agouron Pharmaceuticals, Inc. |
Pyrazole-thiazole compounds, pharmaceutical compositions containing them, and methods of their use for inhibiting cyclin-dependent kinases
|
ATE295354T1
(de)
|
2000-08-18 |
2005-05-15 |
Agouron Pharma |
Heterozyklische-hydroximino-fluorene und ihre verwendung zur inhibierung von proteinkinasen
|
EP1317446A1
(en)
*
|
2000-09-01 |
2003-06-11 |
Glaxo Group Limited |
Oxindole derivatives
|
DE60106947T2
(de)
*
|
2000-09-01 |
2005-11-10 |
Glaxo Group Ltd., Greenford |
Oxindolderivate
|
WO2002020479A1
(en)
|
2000-09-01 |
2002-03-14 |
Glaxo Group Limited |
Substituted oxindole derivatives as tyrosine kinase inhibitors
|
EP1201765A3
(en)
*
|
2000-10-16 |
2003-08-27 |
Axxima Pharmaceuticals Aktiengesellschaft |
Cellular kinases involved in cytomegalovirus infection and their inhibition
|
DE10054019A1
(de)
*
|
2000-11-01 |
2002-05-23 |
Boehringer Ingelheim Pharma |
Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
|
US6638965B2
(en)
|
2000-11-01 |
2003-10-28 |
Boehringer Ingelheim Pharma Kg |
Substituted indolinones, preparation thereof and their use as pharmaceutical compositions
|
DE10117204A1
(de)
|
2001-04-06 |
2002-10-10 |
Boehringer Ingelheim Pharma |
In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
|
SE0101230L
(sv)
*
|
2001-04-06 |
2002-10-07 |
Innoventus Project Ab |
Ny användning av en tyrosinkinasinhibitor
|
WO2002094809A1
(en)
*
|
2001-05-24 |
2002-11-28 |
Yamanouchi Pharmaceutical Co., Ltd. |
3-quinoline-2-(1h)-ylideneindolin-2-one derivatives
|
ATE330608T1
(de)
|
2001-06-29 |
2006-07-15 |
Ab Science |
Die verwendung von n-phenyl-2-pyrimidine-amine derivaten zur behandlung von entzündlichen erkrankungen
|
US7678805B2
(en)
|
2001-06-29 |
2010-03-16 |
Ab Science |
Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (IBD)
|
JP2005500041A
(ja)
|
2001-06-29 |
2005-01-06 |
アブ サイエンス |
強力で選択的かつ非毒性のc−kit阻害剤
|
US20040242612A1
(en)
*
|
2001-09-20 |
2004-12-02 |
Alain Moussy |
Use of tyrosine kinase inhibitors for promoting hair growth
|
CA2461181A1
(en)
*
|
2001-09-20 |
2003-05-01 |
Ab Science |
Use of potent, selective and non-toxic c-kit inhibitors for treating bacterial infections
|
WO2003027109A1
(en)
*
|
2001-09-27 |
2003-04-03 |
Allergan, Inc. |
3-(heteroarylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors
|
US6765012B2
(en)
*
|
2001-09-27 |
2004-07-20 |
Allergan, Inc. |
3-(Arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
|
WO2003033491A1
(fr)
*
|
2001-10-16 |
2003-04-24 |
Nippon Kayaku Kabushiki Kaisha |
Composition medicinale de prevention ou de soulagement d'effets secondaires chez les patients souffrant de cancer et composition anticancereuse medicinale
|
EP1444204A4
(en)
*
|
2001-10-22 |
2009-11-04 |
Univ New York State Res Found |
INHIBITORS OF PROTEIN KINASES AND PROTEINS PHOSPHATASES, METHODS OF IDENTIFICATION AND METHODS OF USE THEREOF
|
US7005445B2
(en)
|
2001-10-22 |
2006-02-28 |
The Research Foundation Of State University Of New York |
Protein kinase and phosphatase inhibitors and methods for designing them
|
US6797825B2
(en)
|
2001-12-13 |
2004-09-28 |
Abbott Laboratories |
Protein kinase inhibitors
|
US20030187026A1
(en)
|
2001-12-13 |
2003-10-02 |
Qun Li |
Kinase inhibitors
|
EP1464645A1
(en)
*
|
2001-12-18 |
2004-10-06 |
Kyowa Hakko Kogyo Co., Ltd. |
Indole derivative
|
US7482366B2
(en)
*
|
2001-12-21 |
2009-01-27 |
X-Ceptor Therapeutics, Inc. |
Modulators of LXR
|
AU2002351412B2
(en)
|
2001-12-21 |
2010-05-20 |
Exelixis Patent Company Llc |
Modulators of LXR
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
FR2836914B1
(fr)
|
2002-03-11 |
2008-03-14 |
Aventis Pharma Sa |
Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
|
KR20040104566A
(ko)
*
|
2002-04-30 |
2004-12-10 |
알콘, 인코퍼레이티드 |
안압 저하 및 녹내장성 망막병증/시신경병증 치료를 위한특유의 수단으로서의 결합 조직 성장 인자 (ctgf)의활성 및/또는 발현 조절, 저해, 또는 변조제
|
MY142390A
(en)
|
2002-05-22 |
2010-11-30 |
Glaxosmithkline Llc |
3' - [(2z)-[1-(3,4-dimethylphenyl)-1,5- dihydro-3- methyl-5-0xo-4h-pyrazol-4- ylidene]hydrazino]-2' -hydroxy -[1,1' -biphenyl]-3-carboxylic acid bis-(monoethanolamine)
|
US7514468B2
(en)
|
2002-07-23 |
2009-04-07 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions
|
US7169936B2
(en)
|
2002-07-23 |
2007-01-30 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments
|
DE10233500A1
(de)
*
|
2002-07-24 |
2004-02-19 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
|
US20040082615A1
(en)
*
|
2002-08-07 |
2004-04-29 |
Michael Konkel |
3-Imino-2-indolones for the treatement of depression and/or anxiety
|
AU2003259689A1
(en)
*
|
2002-08-07 |
2004-02-25 |
Synaptic Pharmaceutical Corporation |
3-imino-2-indolones for the treatment of depression and/or anxiety
|
GB0225873D0
(en)
*
|
2002-11-06 |
2002-12-11 |
Cyclacel Ltd |
Combination
|
AU2003284572A1
(en)
*
|
2002-11-22 |
2004-06-18 |
Yamanouchi Pharmaceutical Co., Ltd. |
2-oxoindoline derivatives
|
ATE354096T1
(de)
|
2002-12-23 |
2007-03-15 |
Astex Therapeutics Ltd |
Synthese und screening von liganden mit hilfe von röntgenkristallographie
|
DK1656372T3
(da)
|
2003-07-30 |
2013-07-01 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidindiaminforbindelser til anvendelse til behandling eller forebyggelse af autoimmunsygdomme
|
TW200526638A
(en)
|
2003-10-22 |
2005-08-16 |
Smithkline Beecham Corp |
2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline
|
GB0328180D0
(en)
*
|
2003-12-04 |
2004-01-07 |
Cyclacel Ltd |
Combination
|
DE102004012069A1
(de)
*
|
2004-03-12 |
2005-09-29 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue aryl-haltige 5-Acylindolinone, deren Herstellung und deren Verwendung als Arzneimittel
|
WO2005118551A2
(en)
*
|
2004-05-28 |
2005-12-15 |
Ligand Pharmaceuticals Inc. |
Thrombopoietin activity modulating compounds and methods
|
CA2583764C
(en)
*
|
2004-10-25 |
2009-06-09 |
Ligand Pharmaceuticals, Inc. |
Thrombopoietin activity modulating compounds and methods
|
GT200500321A
(es)
*
|
2004-11-09 |
2006-09-04 |
|
Compuestos y composiciones como inhibidores de proteina kinase.
|
US20080125432A1
(en)
|
2004-12-01 |
2008-05-29 |
Devgen Nv |
5-Carboxamido Substituted Thiazole Derivatives that Interact With Ion Channels, In Particular With Ion Channels From the Kv Family
|
EP2460408A1
(en)
*
|
2004-12-17 |
2012-06-06 |
deVGen N.V. |
Nematicidal compositions
|
PE20060777A1
(es)
|
2004-12-24 |
2006-10-06 |
Boehringer Ingelheim Int |
Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
|
US7662824B2
(en)
|
2005-03-18 |
2010-02-16 |
Janssen Pharmaceutica Nv |
Acylhydrazones as kinase modulators
|
WO2006119660A1
(en)
*
|
2005-05-11 |
2006-11-16 |
Givaudan Sa |
Encapsulation method
|
JP5225079B2
(ja)
|
2005-06-08 |
2013-07-03 |
ライジェル ファーマシューティカルズ, インコーポレイテッド |
Jak経路の阻害のための組成物および方法
|
US20070203161A1
(en)
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
US7749530B2
(en)
|
2005-07-13 |
2010-07-06 |
Allergan, Inc. |
Kinase inhibitors
|
WO2007008895A1
(en)
*
|
2005-07-13 |
2007-01-18 |
Allergan, Inc. |
Kinase inhibitors
|
CA2602453A1
(en)
|
2005-07-13 |
2007-01-18 |
Allergan, Inc. |
Kinase inhibitors
|
GB0523041D0
(en)
*
|
2005-11-11 |
2005-12-21 |
Cyclacel Ltd |
Combination
|
EP1991532B1
(en)
|
2006-02-24 |
2017-01-11 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
US8987474B2
(en)
*
|
2006-04-07 |
2015-03-24 |
University Of South Florida |
Inhibition of Shp2/PTPN11 protein tyrosine phosphatase by NSC-87877, NSC-117199 and their analogs
|
US7838542B2
(en)
|
2006-06-29 |
2010-11-23 |
Kinex Pharmaceuticals, Llc |
Bicyclic compositions and methods for modulating a kinase cascade
|
US8217177B2
(en)
*
|
2006-07-14 |
2012-07-10 |
Amgen Inc. |
Fused heterocyclic derivatives and methods of use
|
US8036664B2
(en)
*
|
2006-09-22 |
2011-10-11 |
Kineto Wireless, Inc. |
Method and apparatus for determining rove-out
|
KR20090063240A
(ko)
*
|
2006-10-06 |
2009-06-17 |
아이알엠 엘엘씨 |
단백질 키나제 억제제 및 그의 사용 방법
|
GB0625283D0
(en)
*
|
2006-12-19 |
2007-01-24 |
Cyclacel Ltd |
Combination
|
JP5568312B2
(ja)
*
|
2007-02-13 |
2014-08-06 |
アーべー・シオンス |
キナーゼ阻害剤としての2−アミノチアゾール化合物の合成方法
|
WO2008134124A1
(en)
*
|
2007-04-30 |
2008-11-06 |
The Uab Research Foundation |
Ul97 inhibitors for treatment of proliferative disorders
|
ECSP077628A
(es)
|
2007-05-03 |
2008-12-30 |
Smithkline Beechman Corp |
Nueva composición farmacéutica
|
US7863315B2
(en)
*
|
2008-01-15 |
2011-01-04 |
Shenzhen Chipscreen Biosciences, Ltd. |
2-indolinone derivatives as selective histone deacetylase inhibitors
|
EP2265607B1
(en)
|
2008-02-15 |
2016-12-14 |
Rigel Pharmaceuticals, Inc. |
Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases
|
US20110092452A1
(en)
*
|
2008-03-05 |
2011-04-21 |
The Regents Of The University Of Michigan |
Compositions and methods for diagnosing and treating pancreatic cancer
|
US8138339B2
(en)
|
2008-04-16 |
2012-03-20 |
Portola Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
PT2323993E
(pt)
|
2008-04-16 |
2015-10-12 |
Portola Pharm Inc |
2,6-diamino-pirimidina-5-il-carboxamidas como inibidores de quinasses syk ou jak
|
EP2116236A1
(en)
|
2008-04-21 |
2009-11-11 |
Université de Mons-Hainaut |
Bisbenzamidine derivatives for use as antioxidant
|
WO2009131687A2
(en)
|
2008-04-22 |
2009-10-29 |
Portola Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
WO2009135000A2
(en)
*
|
2008-04-30 |
2009-11-05 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Inhibition of shp2/ptpn11 protein tyrosine phosphatase by nsc-117199 and analogs
|
WO2009139834A1
(en)
*
|
2008-05-13 |
2009-11-19 |
Poniard Pharmaceuticals, Inc. |
Bioactive compounds for treatment of cancer and neurodegenerative diseases
|
JP6006938B2
(ja)
|
2008-06-09 |
2016-10-12 |
サイクラセル リミテッド |
スパシタビン(cndac)と、デシタビン及びプロカイン等のdnaメチルトランスフェラーゼ阻害剤との組合せ
|
WO2010039997A2
(en)
*
|
2008-10-01 |
2010-04-08 |
The University Of North Carolina At Chapel Hill |
Hematopoietic protection against chemotherapeutic compounds using selective cyclin-dependent kinase 4/6 inhibitors
|
JP2012504645A
(ja)
*
|
2008-10-01 |
2012-02-23 |
ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル |
健康な細胞に対する電離放射線の影響を低下させる又は防止するための医薬組成物
|
WO2010121212A2
(en)
|
2009-04-17 |
2010-10-21 |
H. Lee Moffit Cancer Center And Research Institute, Inc. |
Indoline scaffold shp-2 inhibitors and method of treating cancer
|
CA2761896A1
(en)
|
2009-05-13 |
2010-11-18 |
The University Of North Carolina At Chapel Hill |
Cyclin dependent kinase inhibitors and methods of use
|
CN102458120A
(zh)
|
2009-05-29 |
2012-05-16 |
葛兰素史密斯克莱有限责任公司 |
给药血小板生成素激动剂化合物的方法
|
EP2459195A1
(en)
*
|
2009-07-28 |
2012-06-06 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
AU2010300531A1
(en)
|
2009-09-30 |
2012-05-24 |
President And Fellows Of Harvard College |
Methods for modulation of autophagy through the modulation of autophagy-inhibiting gene products
|
US8652534B2
(en)
*
|
2009-10-14 |
2014-02-18 |
Berry Pharmaceuticals, LLC |
Compositions and methods for treatment of mammalian skin
|
EP2493895B1
(en)
*
|
2009-10-29 |
2017-04-26 |
Vectura Limited |
N-containing heteroaryl derivatives as jak3 kinase inhibitors
|
WO2011100528A2
(en)
|
2010-02-12 |
2011-08-18 |
Emory University |
Compositions and uses of lectins
|
EP2542528B1
(en)
|
2010-03-02 |
2013-06-19 |
Amakem NV |
Heterocyclic amides as rock inhibitors
|
WO2011161256A1
(en)
|
2010-06-25 |
2011-12-29 |
Facultes Universitaires Notre Dame De La Paix |
Beta carboline derivatives useful in the treatment of proliferative disorders
|
US8785648B1
(en)
|
2010-08-10 |
2014-07-22 |
The Regents Of The University Of California |
PKC-epsilon inhibitors
|
CN103153352B
(zh)
|
2010-08-18 |
2015-07-15 |
爱默蕾大学 |
用于骨化的化合物和组合物以及其相关的方法
|
WO2012022780A1
(en)
|
2010-08-19 |
2012-02-23 |
Université Libre de Bruxelles |
18-beta-glycyrrhetinic acid derivatives with anti-tumor activity
|
CA2961937C
(en)
|
2010-10-25 |
2018-09-25 |
G1 Therapeutics, Inc. |
Cdk inhibitors
|
US8691830B2
(en)
|
2010-10-25 |
2014-04-08 |
G1 Therapeutics, Inc. |
CDK inhibitors
|
CA2816022C
(en)
|
2010-10-29 |
2019-09-10 |
Emory University |
Quinazoline derivatives, compositions, and uses related thereto
|
US9102625B2
(en)
|
2010-11-01 |
2015-08-11 |
Portola Pharmaceuticals, Inc. |
Nicotinamides as JAK kinase modulators
|
GB201019043D0
(en)
|
2010-11-10 |
2010-12-22 |
Protea Biopharma N V |
Use of 2',5'-oligoadenylate derivative compounds
|
EP2640394A4
(en)
|
2010-11-17 |
2015-02-25 |
Univ North Carolina |
PROTECTION OF RENAL TISSUES AGAINST ISCHEMIA THROUGH INHIBITION OF CDK4 AND CDK6 PROLIFERATIVE KINASES
|
EP3153510B1
(en)
|
2010-12-03 |
2020-05-06 |
Emory University |
Fused azines as chemokine cxcr4 receptor modulators and uses related thereto
|
US8691777B2
(en)
|
2011-01-27 |
2014-04-08 |
Emory University |
Combination therapy
|
WO2012116137A2
(en)
|
2011-02-24 |
2012-08-30 |
Emory University |
Jab1 blocking compositions for ossification and methods related thereto
|
WO2012116135A2
(en)
|
2011-02-24 |
2012-08-30 |
Emory University |
Noggin blocking compositions for ossification and methods related thereto
|
WO2012135296A2
(en)
|
2011-03-31 |
2012-10-04 |
Emory University |
Imidazolyl amide compounds and uses related thereto
|
US10226478B2
(en)
|
2011-04-14 |
2019-03-12 |
Cyclacel Limited |
Dosage regimen for sapacitabine and decitabine in combination for treating acute myeloid leukemia
|
EP2699539B1
(en)
|
2011-04-21 |
2019-03-06 |
Emory University |
Cyclopropyl derivatives and methods of use
|
GB201107223D0
(en)
|
2011-04-29 |
2011-06-15 |
Amakem Nv |
Novel rock inhibitors
|
WO2012152807A1
(en)
|
2011-05-09 |
2012-11-15 |
Universiteit Antwerpen |
Activity-based probes for the urokinase plasminogen activator
|
GB201108225D0
(en)
|
2011-05-17 |
2011-06-29 |
Amakem Nv |
Novel KBC inhibitors
|
CA2839956A1
(en)
|
2011-06-20 |
2012-12-27 |
Emory University |
Prostaglandin receptor ep2 antagonists, derivatives, compositions, and uses related thereto
|
GB201113689D0
(en)
|
2011-08-09 |
2011-09-21 |
Amakem Nv |
Novel PDE4 inhibitors
|
EP2744775B1
(en)
|
2011-08-19 |
2018-03-07 |
Emory University |
Bax agonist, compositions, and methods related thereto
|
GB201114854D0
(en)
|
2011-08-29 |
2011-10-12 |
Amakem Nv |
Novel rock inhibitors
|
JP2014525426A
(ja)
|
2011-08-31 |
2014-09-29 |
アマケン エンヴェー |
新規のソフトrock阻害剤
|
KR20140078710A
(ko)
|
2011-09-30 |
2014-06-25 |
온코디자인 에스.에이. |
거대고리 flt3 키나제 억제제
|
US9096609B2
(en)
|
2011-09-30 |
2015-08-04 |
Ipsen Pharma S.A.S. |
Macrocyclic LRRK2 kinase inhibitors
|
GB201119358D0
(en)
|
2011-11-10 |
2011-12-21 |
Lewi Paulus J |
Disubstituted triazine dimers for treatment and/or prevention of infectious diseases
|
DE102011119127A1
(de)
*
|
2011-11-22 |
2013-05-23 |
Merck Patent Gmbh |
3-Cyanaryl-1H-pyrrolo[2.3-b]pyridin-Derivate
|
MX363551B
(es)
|
2011-11-23 |
2019-03-27 |
Portola Pharmaceuticals Inc Star |
Compuestos derivados de pirazina como inhibidores de cinasa.
|
PL2810198T3
(pl)
|
2012-01-30 |
2024-01-22 |
Universiteit Gent |
Związki przeciwinwazyjne
|
GB201204756D0
(en)
|
2012-03-19 |
2012-05-02 |
Lewi Paulus J |
Triazines with suitable spacers for treatment and/or prevention of HIV infections
|
CA2868966C
(en)
|
2012-03-29 |
2021-01-26 |
Francis Xavier Tavares |
Lactam kinase inhibitors
|
WO2013181135A1
(en)
|
2012-05-31 |
2013-12-05 |
Emory University |
Quinazoline derivatives, compositions, and uses related thereto
|
US9593125B2
(en)
|
2012-07-27 |
2017-03-14 |
Emory University |
Heterocyclic flavone derivatives, compositions, and methods related thereto
|
WO2014058921A2
(en)
|
2012-10-08 |
2014-04-17 |
Portola Pharmaceuticals, Inc. |
Substituted pyrimidinyl kinase inhibitors
|
US9877981B2
(en)
|
2012-10-09 |
2018-01-30 |
President And Fellows Of Harvard College |
NAD biosynthesis and precursors for the treatment and prevention of cancer and proliferation
|
EP2914585B1
(en)
|
2012-11-05 |
2018-03-07 |
Emory University |
7,8-dihydroxyflavone and 7,8-substituted flavone derivatives, compositions, and methods related thereto
|
WO2014072419A1
(en)
|
2012-11-08 |
2014-05-15 |
Universiteit Antwerpen |
Novel anti-hiv compounds
|
BR112015018168B1
(pt)
|
2013-01-29 |
2023-04-11 |
Redx Pharma Plc |
Derivados de piridina e composição que os compreende derivados de piridina e composição que os compreende
|
EP2967050A4
(en)
|
2013-03-15 |
2016-09-28 |
G1 Therapeutics Inc |
HIGH-ACTIVE ANTINEOPLASTIC AND ANTIPROLIFERATIVE AGENTS
|
EP2968291A4
(en)
|
2013-03-15 |
2016-09-28 |
G1 Therapeutics Inc |
HSPC-PROOF TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION
|
WO2014140313A1
(en)
|
2013-03-15 |
2014-09-18 |
Oncodesign S.A. |
Macrocyclic salt-inducible kinase inhibitors
|
US9572815B2
(en)
|
2013-03-15 |
2017-02-21 |
St. Jude Children's Research Hospital |
Methods and compositions of p27KIP1 transcriptional modulators
|
KR101548803B1
(ko)
*
|
2013-09-09 |
2015-09-01 |
경북대학교병원 |
3(6(4(트리플루오로메톡시)페닐아미노)피리미딘4일)벤자미드 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 함유하는 당뇨병의 예방 또는 치료용 약학적 조성물
|
PL3043803T3
(pl)
|
2013-09-11 |
2022-11-07 |
Emory University |
Kompozycje nukleotydowe i nukleozydowe oraz ich zastosowanie
|
JP6595463B2
(ja)
|
2013-10-16 |
2019-10-23 |
ユニベルシテ リブレ デ ブリュッセル |
気道に影響する増殖性疾患の処置に有用な製剤
|
CN103588758A
(zh)
*
|
2013-11-04 |
2014-02-19 |
南京大学 |
一类含1,4-苯并二噁烷骨架的硝基咪唑衍生物的合成、制备及其在抗癌药物中的应用
|
NO3068888T3
(es)
|
2013-11-12 |
2018-06-30 |
|
|
AU2014354643B2
(en)
|
2013-11-27 |
2020-03-05 |
Redwood Bioscience, Inc. |
Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
|
KR101602203B1
(ko)
*
|
2014-03-11 |
2016-03-11 |
경북대학교병원 |
N(2하이드록시에틸)3(6(4(트리플루오로메톡시)페닐아미노)피리미딘-4-일)벤자미드 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 함유하는 당뇨병의 예방 또는 치료용 약학적 조성물
|
WO2015150337A1
(en)
|
2014-04-01 |
2015-10-08 |
Amakem Nv |
Lim kinase inhibitors
|
EP3125940A2
(en)
|
2014-04-01 |
2017-02-08 |
Université Libre de Bruxelles |
New strategies for treating melanoma
|
WO2015161288A1
(en)
|
2014-04-17 |
2015-10-22 |
G1 Therapeutics, Inc. |
Tricyclic lactams for use as anti-neoplastic and anti-proliferative agents
|
US9980936B2
(en)
|
2014-05-05 |
2018-05-29 |
Emory University |
BH4 antagonists and methods related thereto
|
US10450293B2
(en)
|
2014-05-16 |
2019-10-22 |
Emory University |
Chemokine CXCR4 and CCR5 receptor modulators and uses related thereto
|
EP3180003B1
(en)
|
2014-07-01 |
2022-01-12 |
The Regents of the University of California |
Pkc-epsilon inhibitors
|
WO2016005340A1
(en)
|
2014-07-08 |
2016-01-14 |
Universiteit Gent |
Hamamelitannin analogues and uses thereof
|
WO2016040858A1
(en)
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Combinations and dosing regimes to treat rb-positive tumors
|
WO2016040848A1
(en)
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
|
MY186523A
(en)
|
2014-09-17 |
2021-07-24 |
Oncodesign Sa |
Macrocyclic rip2 kinase inhibitors
|
DK3194405T3
(en)
|
2014-09-17 |
2019-04-15 |
Oncodesign Sa |
MACROCYCLIC LRRK2 KINase INHIBITORS
|
WO2016083490A1
(en)
|
2014-11-27 |
2016-06-02 |
Remynd Nv |
Compounds for the treatment of amyloid-associated diseases
|
SG10202013032YA
(en)
|
2014-12-15 |
2021-02-25 |
Univ Emory |
Phosphoramidates for the treatment of hepatitis b virus
|
BR112017013858A2
(pt)
|
2014-12-26 |
2018-02-27 |
Univ Emory |
n4-hidroxicitidina e derivados e usos antivirais relacionados aos mesmos
|
WO2016146651A1
(en)
|
2015-03-16 |
2016-09-22 |
Oncodesign Sa |
Macrocyclic activin-like receptor kinase inhibitors
|
WO2016176437A1
(en)
|
2015-04-28 |
2016-11-03 |
Newsouth Innovations Pty Limited |
Targeting nad+ to treat chemotherapy and radiotherapy induced cognitive impairment, neuropathies and inactivity
|
EP3804706B1
(en)
|
2015-05-29 |
2023-08-23 |
Emory University |
2-amino-n'-benzylideneacetohydrazides and derivatives for the management of cftr protein mediated diseases
|
EP3786164A1
(en)
*
|
2015-06-18 |
2021-03-03 |
Ting Therapeutics LLC |
Methods and compositions for the prevention and treatment of hearing loss
|
DK3423113T3
(da)
|
2016-02-29 |
2020-11-30 |
Oncodesign Sa |
Radiomærket makrocyklisk egfr-hæmmer
|
WO2017157882A1
(en)
|
2016-03-14 |
2017-09-21 |
Université Catholique de Louvain |
Serine biosynthetic pathway inhibitors
|
WO2017161253A1
(en)
*
|
2016-03-18 |
2017-09-21 |
Tufts Medical Center |
Compositions and methods for treating and preventing metabolic disorders
|
WO2017189978A1
(en)
|
2016-04-28 |
2017-11-02 |
Emory University |
Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
|
US11166967B2
(en)
|
2016-05-19 |
2021-11-09 |
Universiteit Antwerpen |
Bis(acetamidophenyl) guanidinophenylethylphosphonates for use in the prevention and/or treatment of PAR-related diseases
|
BE1023757B1
(nl)
|
2016-06-30 |
2017-07-12 |
Yun NV |
Bewaring van micro-organismen
|
WO2018065387A1
(en)
|
2016-10-04 |
2018-04-12 |
Universiteit Gent |
Novel hamamelitannin analogues and uses thereof
|
CN109923123B
(zh)
|
2016-10-14 |
2024-01-23 |
爱默蕾大学 |
具有结合或阻断pd-l1的分子的纳米颗粒及其在治疗癌症中的用途
|
EP3532289B1
(en)
|
2016-10-26 |
2024-03-06 |
Emory University |
Polyoxometalate complexes and uses in managing cancer
|
WO2018096088A1
(en)
|
2016-11-24 |
2018-05-31 |
Universiteit Antwerpen |
Halogenated benzotropolones as atg4b inhibitors
|
EP3909598A1
(en)
|
2016-12-13 |
2021-11-17 |
Emory University |
Polypeptides for managing viral infections
|
BR112019013814A2
(pt)
|
2017-01-06 |
2020-01-21 |
G1 Therapeutics Inc |
método para tratamento de câncer ou de um tumor em um indivíduo, composição farmacêutica, combinação, e, kit.
|
WO2018138358A1
(en)
|
2017-01-30 |
2018-08-02 |
Université de Liège |
Perk and ire-1a inhibitors against neurodevelopmental disorders
|
IL292923B2
(en)
|
2017-02-21 |
2024-05-01 |
Univ Emory |
CXCR4 cytokine receptor modulators and related uses
|
WO2018160967A1
(en)
*
|
2017-03-02 |
2018-09-07 |
Board Of Regents, The University Of Texas System |
Indolinone derivatives as inhibitors of maternal embryonic leucine zipper kinase
|
CN106977508A
(zh)
*
|
2017-05-05 |
2017-07-25 |
遵义医学院 |
具有靛红结构的吡唑衍生物用于防治肿瘤的药物及其制法
|
EP3621963B1
(en)
|
2017-05-11 |
2024-01-24 |
Remynd N.V. |
Compounds for the treatment of epilepsy, neurodegenerative disorders and other cns disorders
|
US11661581B2
(en)
*
|
2017-05-25 |
2023-05-30 |
University Of Massachusetts |
Use of CDK inhibitors to enhance growth and self-renewal of progenitor cells
|
WO2019006393A1
(en)
|
2017-06-29 |
2019-01-03 |
G1 Therapeutics, Inc. |
MORPHIC FORMS OF GIT38 AND METHODS OF MAKING SAME
|
KR102626210B1
(ko)
|
2017-12-07 |
2024-01-18 |
에모리 유니버시티 |
N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도
|
EP3773562A1
(en)
|
2018-04-05 |
2021-02-17 |
Universiteit Hasselt |
Selective pde4d inhibitors against demyelinating diseases
|
IL309939A
(en)
|
2018-06-29 |
2024-03-01 |
Rejuvenate Biomed |
Medicinal combination for use in age-related and/or degenerative diseases
|
EP4344743A3
(en)
|
2018-08-07 |
2024-06-19 |
Emory University |
Heterocyclic flavone derivatives, compositions, and methods related thereto
|
EP3840756A4
(en)
|
2018-08-24 |
2022-04-27 |
G1 Therapeutics, Inc. |
IMPROVED SYNTHESIS OF 1,4-DIAZASPIRO[5.5]UNDECAN-3-ONE
|
WO2020047229A1
(en)
|
2018-08-29 |
2020-03-05 |
University Of Massachusetts |
Inhibition of protein kinases to treat friedreich ataxia
|
JP7101311B2
(ja)
*
|
2018-10-05 |
2022-07-14 |
イクノス サイエンシズ エスエー |
Map4k1阻害剤として使用するためのインドリノン化合物
|
US20220227757A1
(en)
|
2019-05-14 |
2022-07-21 |
Suzhou Four Health Pharmaceuticals Co., Ltd. |
Quinazoline-2,4-dione derivatives as parp inhibitors
|
JP2023514443A
(ja)
|
2020-02-24 |
2023-04-05 |
カトリーケ、ユニベルシテート、ルーベン |
ピロロピリジンおよびイミダゾピリジン抗ウイルス化合物
|
GB202003240D0
(en)
|
2020-03-05 |
2020-04-22 |
Ecosynth Nv |
Antiviral treatment
|
US10988479B1
(en)
|
2020-06-15 |
2021-04-27 |
G1 Therapeutics, Inc. |
Morphic forms of trilaciclib and methods of manufacture thereof
|
US11857551B1
(en)
|
2020-07-10 |
2024-01-02 |
Ting Therapeutics Llc |
Methods for the prevention and treatment of hearing loss
|
WO2022157381A1
(en)
|
2021-01-25 |
2022-07-28 |
Universiteit Hasselt |
Phloretin for use in the treatment of neurodegenerative and demyelinating diseases
|
WO2022191501A1
(ko)
*
|
2021-03-12 |
2022-09-15 |
주식회사 온코크로스 |
항암제 내성 암의 치료를 위한 조성물
|
IL310243A
(en)
|
2021-07-26 |
2024-03-01 |
Celcuity Inc |
1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL}PHENYL)-3-[4-(4,6-DIMORHOLIN-4-YL-1,3,5-TRIAZIN-2-YL )PHENYL]urea (GEDATOLISIB) and its combinations for use in cancer treatment
|
EP4377307A1
(en)
|
2021-07-30 |
2024-06-05 |
Confo Therapeutics N.V. |
Compounds for the treatment of pain, in particular neuropathic pain, and/or other diseases or disorders that are associated with at2r and/or at2r mediated signaling
|
WO2023021132A1
(en)
|
2021-08-18 |
2023-02-23 |
Katholieke Universiteit Leuven |
6-substituted- and 6,7-disubstituted-7-deazapurine ribonucleoside analogues
|
WO2023046900A1
(en)
|
2021-09-23 |
2023-03-30 |
Katholieke Universiteit Leuven |
Ribonucleoside analogues against -sars-cov-2
|
WO2023105283A1
(en)
|
2021-12-08 |
2023-06-15 |
Fundacio Privada Institut De Recerca De La Sida - Caixa |
Nucleoside reverse transcriptase inhibitors for use in down syndrome and alzheimer`s disease therapy
|
US11541071B1
(en)
|
2021-12-16 |
2023-01-03 |
Ascletis BioScience Co., Ltd |
Nucleoside derivatives and methods of use thereof
|
WO2023111683A1
(en)
|
2021-12-16 |
2023-06-22 |
Ascletis Bioscience Co., Ltd. |
N4-hydroxycytidine derivatives and use thereof as antiviral agent
|
US11760722B2
(en)
|
2022-01-18 |
2023-09-19 |
Ascletis Bioscience Co., Ltd. |
Inhibitors of cysteine proteases and methods of use thereof
|
WO2023139402A1
(en)
|
2022-01-18 |
2023-07-27 |
Ascletis Bioscience Co., Ltd. |
Inhibitors of cysteine proteases and methods of use thereof
|
WO2023180567A1
(en)
|
2022-03-24 |
2023-09-28 |
Fundacion Privada Institut De Recerca De La Sida-Caixa |
Cyclodextrins for use in coronavirus infection therapy
|
WO2023241799A1
(en)
|
2022-06-15 |
2023-12-21 |
Université Libre de Bruxelles |
Flavanols for use in the treatment of retroviral infections
|
WO2024009120A1
(en)
|
2022-07-08 |
2024-01-11 |
Ascletis Bioscience Co., Ltd. |
Triazine derivatives and methods of use thereof
|
CN116514783A
(zh)
|
2022-11-21 |
2023-08-01 |
歌礼生物科技(杭州)有限公司 |
三嗪衍生物
|